Sitagliptin accepted as monotherapy in Scotland

Sitagliptin has been accepted for restricted use as monotherapy for type-2 diabetes in the NHS in Scotland.

Thee Scottish Medicines Consortium (SMC) has accepted the treatment for patients with type-2 diabetes for whom both metformin and sulphonylureas are inappropriate.

The SMC said that research had shown sitagliptin worked as well as metformin in patients who had received no previous treatment for diabetes.

But, it added, no data are available to compare the effectiveness of sitaglipin with other medicines taken as monotherapy.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus